What is the mechanism of action of CJC-1295 without DAC (Mod GRF 1-29)?

Same GHRH-receptor agonism as DAC variant. Four amino acid substitutions resist enzymatic cleavage. Without the albumin-binding tail, the molecule clears in roughly half an hour — useful for evening dosing that mimics natural sleep-time GH pulse. For healthspan and biological-age applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Same GHRH-receptor agonism as DAC variant. The longevity / hallmarks of aging interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What is the evidence base for CJC-1295 without DAC (Mod GRF 1-29)?

CJC-1295 without DAC (Mod GRF 1-29)'s evidence base sits at mechanistic studies; off-label use widespread. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The longevity / hallmarks of aging interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

How does CJC-1295 without DAC (Mod GRF 1-29)'s half-life affect dosing?

CJC-1295 without DAC (Mod GRF 1-29) has a plasma half-life of ~30 min, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 1-3x daily subq dosing at 100 mcg per dose explains the typical onset timeline for healthspan and biological-age endpoints.

Should I cycle CJC-1295 without DAC (Mod GRF 1-29)?

Standard cycle for CJC-1295 without DAC (Mod GRF 1-29) is 8–12 weeks of 1-3x daily subq 100 mcg dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to CJC-1295 without DAC (Mod GRF 1-29)'s ~30 min half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Home/ Compounds/ CJC-1295 without DAC (Mod GRF 1-29)

CJC-1295 without DAC (Mod GRF 1-29)

Longevity

Healthspan-relevant evaluation of CJC-1295 without DAC (Mod GRF 1-29) starts with mapping its mechanism to the hallmarks of aging and asking which of the nine hallmarks its primary pharmacology engages. Same GHRH-receptor agonism as DAC variant Four amino acid substitutions resist enzymatic cleavage. Without the albumin-binding tail, the molecule clears in roughly half an hour — useful for evening dosing that mimics natural sleep-time GH pulse.. The ~30 min pharmacokinetic profile, the cycle-based 100 mcg 1-3x daily subq dosing pattern, and the longevity-specific stack partners on adjacent hallmarks together produce the framework documented below.

Longevity / Hallmarks of Aging Applications

Autophagy InductionEpigenetic AgingNAD+ MetabolismStem Cell FunctionMitochondrial Biogenesis

Key Takeaways

Longevity lens: CJC-1295 without DAC (Mod GRF 1-29) maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers.
Mechanism: Same GHRH-receptor agonism as DAC variant.
Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles.
Longevity protocol: cycle-based 100 mcg 1-3x daily subq dosing; 8-12 week cycles favoured over continuous administration.
Longevity stack partners: Epithalon, Thymalin, NAD+.

Longevity / Hallmarks of Aging Mechanism

Same GHRH-receptor agonism as DAC variant. Four amino acid substitutions resist enzymatic cleavage. Without the albumin-binding tail, the molecule clears in roughly half an hour — useful for evening dosing that mimics natural sleep-time GH pulse. Healthspan-relevant interpretation of this mechanism asks which biomarkers move, in which direction, on what timescale. The subsections below cover the hallmark mapping, cellular and transcriptional effects, biomarker tracking, and the cycle structure favoured in longevity-research protocols for CJC-1295 without DAC (Mod GRF 1-29).

Healthspan markers and biological age

For users measuring epigenetic age, telomere length, or composite biological-age markers (Horvath, PhenoAge, GrimAge) before and after CJC-1295 without DAC (Mod GRF 1-29) cycles, the question is whether the intervention measurably moves these markers. Current evidence varies by compound but the framework for evaluation is shared: paired pre-post measurement with appropriate inter-test interval.

Cycle-based versus continuous dosing

CJC-1295 without DAC (Mod GRF 1-29)'s longevity protocol is compatible with either cycle-based or continuous dosing depending on the broader stack. The longevity-research convention favours pulsatile and periodic interventions over indefinite continuous administration, on the principle that hormetic stimulation outperforms sustained agonism for systems-biology-relevant endpoints.

Cellular reprogramming and gene expression

Where CJC-1295 without DAC (Mod GRF 1-29) has measurable effects on transcriptional programmes, the direction of effect tends to be toward younger phenotypes rather than away from them. This signature — partial reversal of age-associated expression changes — is what distinguishes a true longevity-relevant compound from a symptomatic one. The signal strength varies, but the direction is what longevity researchers track.

Longevity / Hallmarks of Aging Applications

Inflammaging

Inflammaging maps to one of the hallmarks of aging and is one of the dimensions on which CJC-1295 without DAC (Mod GRF 1-29) is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Mitochondrial Biogenesis

For mitochondrial biogenesis as a longevity-relevant endpoint, CJC-1295 without DAC (Mod GRF 1-29) is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Nutrient Sensing

CJC-1295 without DAC (Mod GRF 1-29)'s contribution to nutrient sensing as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

Stem Cell Function

Stem Cell Function maps to one of the hallmarks of aging and is one of the dimensions on which CJC-1295 without DAC (Mod GRF 1-29) is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60 mcg	4–6 weeks initial cycle
Longevity focus	SubQ	100 mcg	1-3x daily SubQ
Maintenance phase	SubQ	70 mcg	Ongoing with periodic pauses

Dose timing for CJC-1295 without DAC (Mod GRF 1-29) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

CJC-1295 without DAC (Mod GRF 1-29) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.

CJC-1295 without DAC (Mod GRF 1-29) + Epithalon: Identified by Khavinson in St. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in longevity / hallmarks of aging protocols.
CJC-1295 without DAC (Mod GRF 1-29) + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in longevity / hallmarks of aging protocols.
CJC-1295 without DAC (Mod GRF 1-29) + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in longevity / hallmarks of aging protocols.
CJC-1295 without DAC (Mod GRF 1-29) + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in longevity / hallmarks of aging protocols.

Safety & Regulatory Status

WADA: Banned (S2 class) FDA: Unapproved Research: Mechanistic studies; off-label use widespread

Short half-life produces fewer sustained-IGF-1 concerns than DAC variant. Site reactions common. Stack with ipamorelin for synergy.

Lens-specific safety considerations for longevity / hallmarks of aging use of CJC-1295 without DAC (Mod GRF 1-29): Short half-life produces fewer sustained-IGF-1 concerns than DAC variant. Site reactions common. Stack with ipamorelin for synergy. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

CJC-1295 sustained GH release

PMID 16940290

Supporting

Tetra-substituted GHRH analogues

PMID 17684183

CJC-1295 without DAC (Mod GRF 1-29) vs Related Peptides

Compound	Profile	Onset	Best For
CJC-1295 without DAC (Mod GRF 1-29)	Short-acting GHRH analogue	~30 min	Longevity
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies
Thymalin	Thymic polypeptide extract	Variable	A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Does CJC-1295 without DAC (Mod GRF 1-29) actually extend lifespan?

Direct lifespan extension in humans cannot be inferred from current data for any peptide compound. The relevant question is whether CJC-1295 without DAC (Mod GRF 1-29) measurably moves healthspan-relevant biomarkers — epigenetic age, telomere length, inflammatory panels, metabolic flexibility — in the direction of younger phenotypes. Some compounds in this class have measurable effects on these markers; the lifespan extrapolation remains inferential.

When in life should I start CJC-1295 without DAC (Mod GRF 1-29)?

Most longevity-relevant peptides have evidence bases centred on mid-life and later. Earlier use is theoretically reasonable for users with documented age-related markers (elevated inflammation, accelerated epigenetic age) or for compounds whose mechanism is preventative. Below age 35 the benefit for most longevity peptides is theoretical and warrants compound-specific consideration.

Best stack pairing for longevity?

Layered protocols cover multiple hallmarks of aging simultaneously: pineal/telomere (epithalon), thymic/immune (thymalin), mitochondrial (MOTS-c, NAD+), ECM and gene expression (GHK-Cu), and metabolic flexibility (metformin-class or GLP-1-class as appropriate). CJC-1295 without DAC (Mod GRF 1-29) contributes to its specific hallmark layer in this multi-component framework.

How do I know if CJC-1295 without DAC (Mod GRF 1-29) is working?

Track outcome metrics that match the compound's primary mechanism: epigenetic age (DNA methylation panels), inflammatory markers (hsCRP, IL-6), metabolic flexibility (HbA1c, fasting insulin, HOMA-IR), body composition (DEXA), and subjective markers (sleep depth, recovery, well-being). Paired pre-post measurement around cycles is the standard framework.

What is the standard dosing protocol for CJC-1295 without DAC (Mod GRF 1-29)?

Conventional CJC-1295 without DAC (Mod GRF 1-29) dosing is 100 mcg 1-3x daily subq via subq. For healthspan and biological-age use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What does CJC-1295 without DAC (Mod GRF 1-29) stack well with?

For longevity / hallmarks of aging protocols, CJC-1295 without DAC (Mod GRF 1-29) pairs with compounds on complementary pathways: Epithalon, Thymalin, NAD+. These pairings are selected because they engage independent receptor systems from CJC-1295 without DAC (Mod GRF 1-29)'s primary mechanism (Same GHRH-receptor agonism as DAC variant), producing additive or synergistic effects rather than receptor competition.

Clinical Protocol

Start a CJC-1295 without DAC (Mod GRF 1-29) Protocol

Alukard provides physician-supervised longevity protocols with GMP-certified CJC-1295 without DAC (Mod GRF 1-29) and GMP-certified compounds with biological age testing and healthspan markers.

Get Protocol

Quick Facts

Molecular weight: ~3367 Da
Sequence length: 29 aa
Half-life: ~30 min
WADA: Banned (S2 class)
FDA: Unapproved
Research: Mechanistic studies; off-label use widespread

Stack Partners

Epithalon

Thymalin

NAD+

MOTS-c

GHK-Cu

Research Note

All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 without DAC (Mod GRF 1-29) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised longevity protocols

Start Your Longevity / Hallmarks of Aging Protocol for CJC-1295 without DAC (Mod GRF 1-29)

Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised